Blood pressure and vascular effects of endothelin blockade in chronic nitric oxide-deficient hypertension

Hypertension

Volumn 29, Issue 3, 1997, Pages 763-769

  Moreau, Pierre ^c   Takase, Hiroyuk ^c   Küng, Christoph F ^c   Shaw, Sidney ^a   Lüscher, Thomas F ^b  

^a BERN UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c NONE

Author keywords

blood vessels; endothelins; hypertension, experimental

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; ACETYLCHOLINE; ANGIOTENSIN; BOSENTAN; ENDOTHELIN 1; ENDOTHELIN RECEPTOR ANTAGONIST; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE INHIBITOR; NITROPRUSSIDE SODIUM; NORADRENALIN; PLACEBO; POTASSIUM CHLORIDE; SEROTONIN; THROMBOXANE A2 RECEPTOR STIMULATING AGENT; VASOCONSTRICTOR AGENT;

ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTICLE; BASILAR ARTERY; BLOOD PRESSURE REGULATION; BLOOD VESSEL REACTIVITY; CONTROLLED STUDY; ESSENTIAL HYPERTENSION; EXPERIMENTAL MODEL; MALE; MESENTERIC ARTERY; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; RESISTANCE BLOOD VESSEL; VASCULAR ENDOTHELIUM;

EID: 0031037765     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.29.3.763     Document Type: Article

References (28)

1. Lüscher TF, Seo B-G. Bühler FR. Potential role of endothelin in hypertension: controversy on endothelin in hypertension. Hypertension. 1993;21:752-757.
2. Wilkins FC, Alberola A, Mizelle HL, Opgenorth TJ, Granger JP. Chronic pathophysiological circulating endothelin levels produce hypertension in conscious dogs. J Cardiovasc Pharmacol. 1993;22 (suppl 8):S325-S327.
3. Vanhoutte PM. Is endothelin involved in the pathogenesis of hypertension? Hypertension. 1993;21:747-751.
4. Li JS, Larivière R, Schiffrin EL. Effect of a nonselective endothelin antagonist on vascular remodeling in deoxycorticosterone acetate-salt hypertensive rats: evidence for a role of endothelin in vascular hypertrophy. Hypertension. 1994;24:183-188.
5. Li J-S, Schiffrin EL. Effect of chronic treatment of adult spontaneously hypertensive rats with an endothelin receptor antagonist. Hypertension. 1995;25:495-500.
6. Bird JE, Moreland S, Waldron TL, Powell JR. Antihypertensive effects of a novel endothelin-A receptor antagonist in rats. Hypertension. 1995;25:1191-1195.
7. Nishikibe M, Ikada M, Tsuchida S, Fukuroda T, Shimamoto K, Kobayashi M, Ishikawa K, Yano M, Ikemoto F. Antihypertensive effect of a newly synthesized endothelin antagonist. BQ-123, in genetic hypertension models. J Hypertens. 1992;10(suppl 4):53.
8. A) receptor antagonist in conscious rats. J Cardiovasc Pharmacol. 1992;20:940-948.
9. McMahon EG, Palomo MA, Brown MA, Bertenshaw SR, Carter JS. Effect of phosphoramidon (endothelin converting enzyme inhibitor) and BQ-123 (endothelin receptor subtype A antagonist) on blood pressure in hypertensive rats. Am J Hypertens. 1993;6:667-673.
10. Boulanger C, Lüscher TF. Release of endothelin from the porcine aorta: inhibition by endothelium-derived nitric oxide. J Clin Invest. 1990;85:587-590.
11. Boulanger C, Lüscher TF. Hirudin and nitric oxide donors inhibit the thrombin-induced release of endothelin from the intact porcine aorta. Circ Res. 1990;68:1768-1772.
12. Qiu C, Engels K, Baylis C. Endothelin modulates the pressor action of acute systemic nitric oxide blockade. J Am Soc Nephrol. 1995; 6:1476-1481.
13. Richard V, Hogie M, Clozel M, Löffler B-M, Thuillez C. In vivo evidence of an endothelin-induced vasopressor tone after inhibition of nitric oxide synthesis in rats. Circulation. 1995;91:771-775. Abstract.
14. Thompson A, Valeri CR, Lieberthal W. Endothelin receptor A blockade alters hemodynamic response to nitric oxide inhibition in the rat. Am J Physiol. 1995;269:H743-H748.
15. Moreau P, Takase H, Küng CF, van Rooijen M-M, Schaffner T, Lüscher TF. Structure and function of the rat basilar artery during chronic nitric oxide synthase inhibition. Stroke. 1995;26:1922-1929.
16. Takase H, Moreau P, Küng CF, Nava E. Lüscher TF. Antihypertensive therapy improves the endothelial function of resistance arteries in nitric oxide deficient hypertension: effect of verapamil and trandolapril. Hypertension. 1996;27:25-31.
17. 2 receptor antagonists inhibit endothelium-dependent contractions. Hypertension. 1990;15:699-703.
18. Soerensen S. Radioimmunoassay of endothelin in human plasma. Scand J Lab Invest. 1991;51:615-623.
19. Wallenstein S, Zucker CL, Fleiss JL. Some statistical methods useful in circulation research. Circ Res. 1980;47:1-9.
20. Heagerty AM, Aalkjaer C, Bund SJ, Korsgaard N, Mulvany MJ. Small artery structure in hypertension: dual process of remodelling and growth. Hypertension. 1993;21:391-397.
21. Bank N, Aynedjian HS, Khan GA. Mechanism of vasoconstriction induced by chronic inhibition of nitric oxide in rats. Hypertension. 1994;24:322-328.
22. Deng LY, Thibault G, Schiffrin EL. Effect of hypertension induced by nitric oxide synthase inhibition on structure and function of resistance arteries in the rat. Clin Exp Hypertens. 1993;15:527-537.
23. Dunn WR, Gardiner SM. No evidence for vascular remodelling during hypertension induced by chronic inhibition of nitric oxide synthase in Brattleboro rats. J Hypertens. 1995;13:849-857.
24. G-nitro-L-arginine methyl ester-induced hypertension: methodological considerations for studies of small arteries in hypertension. J Hypertens. 1995;13:817-821. Editorial.
25. Küng CF, Moreau P, Takase H, Lüscher TF. L-NAME-induced hypertension impairs endothelial function in rat aorta: reversal by trandolapril and verapamil. Hypertension. 1995;26:744-751.
26. G-nitro-L-arginine methyl ester to the rat on inhibition of nitric oxide-mediated responses. Br J Pharmacol. 1995;114:1673-1679.
27. Moreau P, Takase H, Lüscher TF. Effect of endothelin antagonists on the response to prostanoid endothelium-derived contracting factor. Br J Pharmacol. 1996;118:1429-1432.
28. Li J-S, Schiffrin EL. Resistance artery structure and neuroeffector mechanisms in hypertension induced by inhibition of nitric oxide synthase. Am J Hypertens. 1994;7:996-1004.